SA PRO
Free Account
Inovio Pharmaceuticals, Inc.INONASDAQ
LOADING
|||
OverviewChartsNewsFundamentalsEarningsAnalysts

Analyst Sentiment

Analysts are neutral — opinion is divided on direction.

Consensus Rating
Hold
16 analysts·Moderate coverage
56%
Rating Distribution
Strong Buy
00%
Buy
956%
Hold
531%
Sell
213%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Earnings & Revenue Estimates

Earnings Surprises

Recent Analyst Actions

Nov 14, 2025Piper Sandler
'Inovio Pharmaceuticals (INO) Raises $28.75M to Fund Operations'; PT Raised at Piper Sandler
Target:$6.00
+201.5%from $1.99
Aug 9, 2024RBC Capital
Inovio Pharmaceuticals (INO) PT Lowered to $8 at RBC Capital
Target:$8.00
-8.2%from $8.71
May 14, 2024Oppenheimer
Oppenheimer Reiterates Outperform Rating on Inovio Pharmaceuticals (INO)
Target:$40.00
+249.5%from $11.45
May 13, 2024Stephens
Inovio initiated with an Overweight at Stephens
Target:$20.00
+76.1%from $11.36
Jan 25, 2024Oppenheimer
Oppenheimer Upgrades Inovio Pharmaceuticals (INO) to Outperform
Target:$4.00
-41.1%from $6.79

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance